Notable Labs (NTBLQ) AI Stock Analysis

• Market Cap: $10.00
• Dividend Yield: N/A
• Average Volume (3M): 50.33K
• Price to Earnings (P/E): ―
• Beta (1Y): -53.22
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 9,659,496
• 10 Day Avg. Volume: 43,656
• 30 Day Avg. Volume: 50,326
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 30 Underperform
• Price Target: ―

Notable Labs is currently in a challenging position with significant financial performance issues, including ongoing losses and negative cash flows. Technical analysis reflects bearish sentiment, and the valuation is unattractive due to a negative P/E ratio. The substantial decline in stock price following the recent earnings announcement underscores market concern. Despite potential growth within the biotechnology sector, significant improvements in financial health are needed.

Positive Factors

Partnership Revenue Model

The company's revenue model, based on strategic partnerships, provides a scalable path to growth by leveraging external expertise and resources.

Biotechnology Industry Growth

The biotechnology sector's growth potential offers a favorable backdrop for Notable Labs to expand its market presence and capitalize on industry trends.

Manageable Debt Levels

Low leverage provides financial flexibility and reduces risk, allowing the company to focus on strategic investments and operational improvements.

Negative Factors

Ongoing Losses

Persistent losses hinder the company's ability to reinvest in growth opportunities and may necessitate additional financing, impacting long-term sustainability.

Negative Cash Flows

Negative cash flows indicate operational inefficiencies and reliance on external funding, which could constrain future growth and financial stability.

Profitability Challenges

Ongoing profitability issues limit the company's ability to generate shareholder value and reinvest in R&D, crucial for long-term competitiveness.

Notable Labs Business Overview & Revenue Model

Company Description

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

How the Company Makes Money

Notable Labs generates revenue primarily through partnerships and collaborations with pharmaceutical companies and research institutions. The company offers its platform as a service to these partners, who use it to screen and identify promising drug candidates more efficiently. Additionally, Notable Labs may engage in licensing agreements, allowing partners to use its technology in exchange for fees or royalties. The company's business model is heavily reliant on its ability to form strategic alliances and demonstrate the value of its platform in accelerating drug development.

Notable Labs Financial Statement Overview

Summary

Notable Labs faces significant financial challenges, with ongoing losses and cash flow issues. While there are signs of revenue growth and manageable debt levels, the company must address its profitability and cash generation to improve its financial health. The biotechnology industry context suggests potential for growth, but financial stability remains a concern.

Income Statement

Notable Labs has faced significant challenges in its income statement, with consistent losses over the years. Gross profit margin is positive, but the company is struggling with negative net income and EBIT margins. Revenue has shown volatility, with a significant increase in the latest period, but profitability remains a concern.

Balance Sheet

The balance sheet shows some improvement, with positive stockholders' equity and manageable total debt. However, high liabilities compared to assets and fluctuating equity levels pose risks. The debt-to-equity ratio is relatively low, reflecting limited leverage, but overall financial stability is moderate.

Cash Flow

Cash flow analysis reveals consistent negative operating and free cash flows, indicating challenges in generating cash from operations. The company has relied on financing to support its cash position. The ratio of operating cash flow to net income is less favorable, reflecting ongoing cash management issues.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	―	―	―	―	―
Gross Profit	113.00K	8.00K	403.00K	528.00K	340.00K
EBITDA	-14.40M	-12.60M	-16.59M	-22.92M	-19.73M
Net Income	-11.26M	-14.41M	-16.05M	-24.23M	-21.14M
Balance Sheet
Total Assets	19.54M	5.51M	64.66M	41.70M	49.01M
Cash, Cash Equivalents and Short-Term Investments	―	―	―	―	―
Total Debt	2.05M	361.00K	2.35M	2.53M	2.94M
Total Liabilities	4.43M	7.13M	12.48M	10.79M	12.98M
Stockholders Equity	―	―	―	―	―
Cash Flow
Free Cash Flow	-13.78M	-11.59M	-26.45M	-23.42M	25.51M
Operating Cash Flow	-13.72M	-11.64M	-24.98M	-23.37M	25.58M
Investing Cash Flow	―	―	―	―	―
Financing Cash Flow	―	―	―	―	―

Notable Labs Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTBLQ, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.31 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NTBLQ.

Notable Labs Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GRI	45 Neutral	$4.88M	―	-248.95%	―	―	98.45%
ONCO	33 Underperform	$5.33M	―	-254.09%	―	-9.34%	93.84%
NTBLQ	30 Underperform	$10.00	―	―	―	―	―
SLRX	30 Underperform	$4.14M	-0.08	-660.37%	―	―	74.27%
PCSA	29 Underperform	$15.41M	―	-212.38%	―	―	57.99%
QNRX	25 Underperform	$7.62M	-0.03	-244.31%	―	―	-146.64%